Hackensack Meridian San Antonio Breast Cancer Review 2024

A concise, case-based update distilling the most practice-changing findings from the San Antonio Breast Cancer Symposium (SABCS). Faculty translate new trial data and guidelines into clear diagnostic and therapeutic pathways for clinic and tumor board.
What You Will Learn

How to integrate recent evidence into screening, staging, and biomarker-driven treatment

Selection and sequencing of systemic therapy across HR+, HER2+, and triple-negative disease

Practical use of genomic assays, residual disease tools, and MRD/ctDNA where applicable

Toxicity prevention and management for targeted agents and immunotherapies

Survivorship care plans: bone health, fertility, cardiometabolic risk, and symptom control

Event Details

Format: Focused lectures, case panels, and interactive Q&A with take-home checklists

Structure: Disease-subtype blocks plus cross-cutting sessions on imaging, surgery/radiation, and supportive care

Access: Built for rapid implementation in community and academic settings

Who Should AttendMedical, surgical, and radiation oncologists; breast imaging specialists; oncology pharmacists and nurses; advanced practice providers; tumor-board members; fellows/trainees.
Why Attend

Convert fresh SABCS data into simple, actionable algorithms

Align multidisciplinary decisions across surgery, radiation, and systemic therapy

Improve patient experience with clear counseling scripts and follow-up pathways

+ Topics:
*Note: these are continuous video recordings during the conference, they include individual lectures mentioned in the below

HR+ disease: endocrine backbones, CDK4/6 use, escalation/de-escalation strategies

HER2+ disease: neoadjuvant/adjuvant choices, antibody–drug conjugates, brain metastasis considerations

Triple-negative: chemo–IO combinations, ADCs, germline/somatic targeting

Genomics & biomarkers: assays for prognosis/prediction, ctDNA/MRD concepts, pathology reporting pearls

Local therapy: surgical margins, axillary management, radiation indications and partial-breast options

Supportive care: toxicity mitigation, bone/cardiac health, fertility and menopause management, survivorship